Arctic Bioscience AS

Arctic Bioscience AS FCF/Debt

The Free Cash Flow to Debt Ratio of Arctic Bioscience AS (ABS.OL) as of Oct 23, 2026 is -165.99 %. In the previous year, Free Cash Flow to Debt Ratio was -292.69 % — a change of -43.29% (higher).

FCF/Debt

-165.99 %

YoY

-43.29%

Last updated:

Free Cash Flow to Debt Ratio of Arctic Bioscience AS is 2025 -165.99 % . Free Cash Flow to Debt Ratio of Arctic Bioscience AS was 2024 -292.69 % . It decreases by -43.29% higher compared to the previous year.

The Arctic Bioscience AS FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
-157.47 NOK
Jan 1, 2020
-417.74 NOK
Jan 1, 2021
-1.82 M NOK
Jan 1, 2022
-7,656.33 NOK
Jan 1, 2023
-4,179.20 NOK
Jan 1, 2024
-292.69 NOK
Jan 1, 2025
-165.99 NOK
The Arctic Bioscience AS FCF/Debt history
YEARFCF/DebtYoY
-165.99 %-43.29%
-292.69 %-93.00%
-4,179.20 %-45.42%
-7,656.33 %-99.58%
-1.82 M %+434,604.49%
-417.74 %+165.28%
-157.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arctic Bioscience AS Stock analysis

What does Arctic Bioscience AS do? Arctic Bioscience AS develops marine ingredients from herring roe for autoimmune disorder therapies, focusing on HRO350 for psoriasis treatment. The company markets B2B products like herring caviar oil and protein through subsidiaries such as Arctic Nutrition AS and Romega AS, which produces omega-3 supplements in capsule form. Its product Romega targets consumers seeking dietary supplements, while B2B segments buy herring roe-derived ingredients for further processing. The firm's subsidiaries handle distinct segments: Arctic Nutrition AS focuses on nutritional products, Romega AS on dietary supplements, and Arctic Biopharma AS on drug development. Arctic Bioscience AS generates revenue through B2B sales of herring caviar oil and protein, alongside consumer sales of Romega omega-3 capsules. HRO350 remains in development but is positioned for future therapeutic sales. Subsidiaries like Romega AS directly serve end-users with dietary supplements, while Arctic Nutrition AS and Arctic Biopharma AS support B2B and clinical development needs. The company’s strategy aligns with its purpose of providing marine membrane lipid-based therapies for autoimmune conditions. The firm’s revenue streams include Romega’s omega-3 dietary supplements sold to consumers and herring caviar oil/protein sold to businesses. Arctic Nutrition AS and Romega AS operate within the B2B and consumer markets, respectively, while Arctic Biopharma AS develops HRO350 for psoriasis treatment. All products derive from herring roe extraction, with no additional brands or products mentioned in the business description. Arctic Bioscience AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arctic Bioscience AS stock

Free Cash Flow to Debt Ratio of Arctic Bioscience AS is -165.99 % in 2025.

Free Cash Flow to Debt Ratio of Arctic Bioscience AS changed from -292.69 % to -165.99 %, representing a -43.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Arctic Bioscience AS since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Arctic Bioscience AS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Arctic Bioscience AS

All Key Metrics — Arctic Bioscience AS